Linerixibat

Key Takeaways

• Linerixibat approved March 2026 for PBC‑related itch
• Phase 3 GLISTEN trial showed 21% itch‑free at 24 weeks
• Blocks ileal bile‑acid reuptake, lowering systemic bile acids
• First FDA‑cleared oral therapy targeting cholestatic pruritus

Pulse Analysis

Primary biliary cholangitis remains a chronic liver disease where the standard of care, ursodeoxycholic acid, controls cholestasis but does little for the debilitating itch that many patients experience. This pruritus stems from excess bile acids circulating in the bloodstream, a symptom that can lead to sleep disruption, depression, and reduced work productivity. As clinicians seek symptom‑focused solutions, the market has been primed for a therapy that directly addresses bile‑acid dysregulation rather than merely slowing disease progression.

Linerixibat, marketed as Lynavoy®, is an oral inhibitor of the apical sodium‑dependent bile‑acid transporter (ASBT), also known as the ileal bile‑acid transporter (IBAT). By preventing reabsorption of bile acids in the ileum, the drug reduces the enterohepatic pool, thereby lowering systemic bile‑acid concentrations that trigger itch receptors. The pivotal GLISTEN Phase 3 trial enrolled patients with moderate‑to‑severe cholestatic pruritus and demonstrated that 21% achieved complete itch resolution after 24 weeks, compared with negligible change in the placebo arm. Safety data showed a tolerable profile, with mild gastrointestinal events being the most common adverse effects.

The FDA’s March 2026 approval positions linerixibat as the first oral agent specifically indicated for cholestatic pruritus, opening a new revenue stream for its developer and prompting competitors to explore similar IBAT inhibition strategies. Payers are likely to view the drug favorably given its potential to reduce ancillary costs associated with sleep aids, antidepressants, and hospital visits for severe itch. Moreover, the approval may accelerate research into broader applications of ASBT inhibition, such as in non‑alcoholic fatty liver disease or metabolic disorders, reinforcing the therapeutic relevance of bile‑acid modulation across hepatology and beyond.